Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified October 2014 by QuantumLeap Healthcare Collaborative
Sponsor:
Information provided by (Responsible Party):
QuantumLeap Healthcare Collaborative
ClinicalTrials.gov Identifier:
NCT01042379
First received: December 31, 2009
Last updated: October 13, 2014
Last verified: October 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: November 2015
  Estimated Primary Completion Date: September 2015 (Final data collection date for primary outcome measure)